The development of analytical techniques such as accelerator mass spectrometry (AMS) and highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) allows assessment of bioavailability and plasma pharmacokinetics (PKs) in human subjects using a microdose (less than 100 μg) of drug.1–3 Microdosing studies would allow early screening in human before extensive animal toxicity studies and good manufacturing practice scale-up for phase I clinical studies to help identify the most promising drug candidates. It is not clear whether the kinetics of a microdose of a drug in vivo can predict the PK of a much larger therapeutic dose. However, there is mounting evidence that microdosing results are predictive of plasma PK and metabolism at the therapeutic dose level across a wide range of different chemical classes.4,5
The efficacy and toxicity of many human drugs depend on transport into target cells followed by conversion to an active or toxic metabolite. There are many nucleoside analog drugs whose efficacy depends on intracellular phosphorylation, including those used in anti-HIV treatment, viral hepatitis, and cancer. Little is known about the PK of intracellular phosphorylation of these drugs in microdosing studies. In a previous trial, we have demonstrated that it is feasible to detect 14C-labeled zidovudine-triphosphate (ZDV-TP) using AMS technology with high sensitivity, and we have successfully cross-validated these results using standard LC-MS/MS analysis.6 With this technique, we can thus directly compare the PK of intracellular phosphorylation in microdose and standard dose studies.
ZDV, a thymidine analog, and tenofovir (TFV), an adenosine analog, are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) used in HIV treatment and prevention. These drugs are phosphorylated by different intracellular pathways.7,8 We used 14C-labeled ZDV and 14C-labeled tenofovir disoproxil fumarate (TDF) as model drugs to compare the PK of the active intracellular phosphorylated anabolite [(ZDV-TP and TFV-diphosphate (TFV-DP)], in total peripheral blood mononuclear cells (PBMCs) and isolated CD4+ T cells in vivo with both a microdose regimen and a standard dose regimen using AMS.
The PK of the active intracellular drug metabolite is important in evaluating the efficacy and toxicity of a drug and in choosing a dosing regimen. Evidence suggests that ZDV phosphorylation may be greatly reduced in CD4+ lymphocytes,9 which are the major target population for HIV infection, but no direct comparisons of TFV phosphorylation in T-cell subsets have been published. Here, we directly compare TFV-DP and ZDV-TP measured in PBMCs and CD4+ T cells in subjects receiving a microdose or therapeutic dose of TDF.
Subjects and Study Design
This protocol was reviewed and approved by the Johns Hopkins Medicine Institutional Review Board and Radioactive Drug Review Committee, and all subjects signed informed consent approved by the Institutional Review Board. All subjects underwent a screening history and physical examination up to 28 days before participation. Enrolment criteria included age 18–55 years, normal renal function based on calculated creatinine clearance, hemoglobin >12 g/dL, HIV seronegative, and no medications or dietary supplements within 7 days before the study. No medications or supplements were allowed during the study.
This was a fixed-sequence study with 2 arms (ZDV arm and TDF arm). Six healthy subjects were enrolled for each arm. All 12 subjects received a microdose (20 μCi/100 μg) of 14C labeled drug (ZDV or TDF) at first visit, and after a washout period of at least 30 days, all subjects received a standard dose (20 μCi/300.1 mg) of drug (ZDV or TDF). Detailed dosing information is described in the Supplemental Digital Content (http://links.lww.com/QAI/A355).
Chemicals and Materials
14C-labeled ZDV [2-14C-], ZDV-TP, and 14C-labeled TDF [adenine-8-14C-] were obtained from Moravek Biochemicals, Inc. (Brea, CA). High performance liquid chromatography-grade water and methanol were purchased from VWR (Bridgeport, NJ). Analytical grade potassium chloride, sodium acetate, and acid phosphatase were acquired from Sigma–Aldrich Corp. (St Louis, MO). Waters XTerra MS C18 2.5-μm, 2.1 mm × 50 mm columns, Waters Accell Plus QMA Cartridges, and Waters OASIS HLB Extraction Cartridge were purchased from Waters Corporation (Milford, MA).
Sample Collection and Processing
PK samples for plasma, PBMCs, and fractionated CD4+ T-lymphocytes were obtained predose, 2, 4, 8, 12, and 24 hours postdosing in the ZDV arm and predose, 4, 12, 24, 72, and 168 hours postdosing in the TDF arm. At designated time points, 40 mL of blood was collected from each subject in CPT tubes (Becton, Dickinson and Company, Franklin Lakes, NJ) for the isolation of PBMCs. Two-thirds of the PBMCs were used to isolate CD4+ cells by MACS cell separation with CD4 microbeads and LS columns (Miltenyi Biotec, Bergisch Gladbach, Germany), as previously described.10 Cells were washed and counted. Four milliliters of plasma were saved from the same samples for later PK analysis of parent drug concentrations.
For PBMCs and CD4+ cells obtained from 40 mL of blood, cells were counted and lysed as 107 cells/250 μL buffer (70% methanol) and stored at −80°C. Samples with cell counts less than 107 were lysed in 250 μL of buffer. All cell extracts were processed using solid phase exchange cartridges to separate ZDV/TFV phosphates from parent drug and other anabolites, as described.11,12 Phosphate fractions and plasma samples were sent on dry ice for analysis by AMS.
AMS and PK Analysis
AMS analyses were conducted at the MIT BEAMS Lab using procedures described in the Supplemental Digital Content (http://links.lww.com/QAI/A355).13 PK parameters were derived by noncompartmental analysis using WinNonlin (Pharsight, Sunnyvale, CA) version 5.0.1. The elimination rate constant (k e) was determined from the natural log-transformed data, using linear regression analysis. Elimination half-life was calculated from the following equation: t 1/2 = In2/K e. All values below the limit of quantification (BQL) before Tmax was set at 0; the first BQL value after Tmax was set at half the BQL value; the rest of BQL readings were not used in the analysis.
To compare the PK profiles between the microdose and standard dose regimen, we performed the Wilcoxon signed rank test. The same test was used to determine PK differences in CD4+ cells and PBMCs. A P value < 0.05 was considered to be statistically significant. All statistical analyses were performed by SPSS 19.0 (IBM, Armonk, NY).
Twelve HIV-seronegative subjects (11 men and 1 woman; 8 African Americans and 4 whites), aged 35–55 years and with body mass index of 20.1–31.5 kg/m2, were randomized into 2 arms. All subjects tolerated study procedures without clinically significant adverse events.
Detection of Parent Drug and Intracellular Triphosphates
The AMS data were reported as disintegrations per minute and converted to mass concentrations as previously described,6 based on a drug ratio of 100 μg drug/20 μCi for the microdose phase and 300.1 mg drug/20 μCi for the standard dose phase. Only AMS analysis was carried out on these samples because of assay sensitivity limits for LC-MS/MS in the microdose phase and based on prior comparisons of the accuracy of AMS versus LC-MS/MS, with correlation coefficient of 0.96 and ratio of AMS to LC-MS/MS measurement at 1.03 (90% confidence interval: 0.92 to 1.17).6
For ZDV, in all postdose samples for all 6 subjects, ZDV and ZDV-TP were detectable by AMS. For TFV, TFV-DP was not detectable in the CD4+ cell subset postdose in the microdose regimen for a single subject. For both drugs, predose samples in plasma for the second phase of the study were all below detection limits by AMS. In PBMCs, 2 subjects in each arm had a higher than lower limit of quantification (LLOQ) signal at predose during the second phase of the study, although these concentrations were barely higher than the LLOQ. The normalized carryover from microdose phase were less than 1% of standard dose Cmax for ZDV-TP and less than 5% of standard dose Cmax for TFV-DP in predose samples. LLOQ values were never higher than 0.021 dpm/mL, but they varied as a function of instrument condition.
Comparison of Plasma PK After a Microdose Versus a Standard Therapeutic Dose of NRTIs
In the ZDV arm, the concentration–time plot (Fig. 1A) shows that the total plasma 14C (including both 14C-ZDV and its major metabolite 14C-ZDV-glucuronide as AMS cannot discriminate between these moieties) was similar comparing the microdose and standard dosing regimens. With our limited sampling time points, Tmax occurred at 2 hours for all subjects in both dosing regimens. For the microdose regimens, normalized median Cmax for ZDV equivalent (parent drug plus circulating metabolites) was 0.7-fold lower compared with that of the standard dose (Tables 1 and 2). In all 6 subjects, calculated Cmax was lower with the microdose regimen (Wilcoxon signed rank test, P = 0.03), whereas the microdose predicted area under the curve from zero to infinity (AUCinf) was higher in one subject and lower in 5 subjects (Wilcoxon signed rank test, P = 0.08). Noncompartmental analysis calculated plasma ZDV clearance (CL/F), apparent volume of distribution (Vd/F), and half-life for both microdose and standard dose (Table 1). The ratios of all PK parameters derived from the 2 dosing regimens were within a factor of 2 (Table 2), indicating reasonable concordance of ZDV plasma PK as assessed by the microdose and standard dose.
For the TDF arm, 14C signal in plasma is mostly TFV.14,15 The concentration–time plot is shown in Figure 1B. With the microdose regimen, normalized plasma TFV concentrations were higher compared with the standard dosing regimen (Fig. 1B). The Tmax for plasma TFV was detected at 4 hours for all subjects in both regimens. For the microdose regimen, median normalized Cmax and AUCinf were 1.5 times higher compared with that of the standard dose. Normalized Cmax and AUCinf calculated after the microdose were higher in all 6 subjects (Wilcoxon signed rank test, P = 0.03). Noncompartmental analysis showed that all the plasma PK parameters [clearance (CL/F), apparent volume of distribution (Vd/F), and half life (T 1/2)] were similar in microdose and standard dose regimens, with ratios less than 2 (Tables 1 and 2).
Comparison of PK of Intracellular Phosphorylated Metabolites After a Microdose Versus a Standard Therapeutic Dose of NRTIs
Figures 1C, D illustrate the concentration–time plots for ZDV-TP in total PBMCs and isolated CD4+ cells. The Tmax for intracellular ZDV-TP was observed at 2 hours for all cell types, and the intracellular 14C-ZDV-TP Cmax and AUCinf were higher with the microdose regimen for all 6 subjects (P = 0.03) for both PBMC and CD4+ cells. In PBMCs, the median ratio of normalized Cmax for ZDV-TP was 4.5-fold higher (291.9 versus 85.5 fmol/106 cells) after the 100 μg microdose versus 300 mg dose of ZDV. In the CD4+ cells, the median normalized Cmax of intracellular ZDV-TP was 17-fold higher (204.2 versus 15.0 fmol/106 cells) after microdosing compared with standard dosing (Tables 1 and 2). Noncompartmental analysis indicated that for PBMCs, the AUCinf of intracellular ZDV-TP changed 3.9-fold over the dose range studied (100 μg to 300 mg). In CD4+ cells, the AUCinf of ZDV-TP changed 12.9-fold over the same dose range (Table 2).
For TFV-DP, we observed a plateau between 12 and 72 hours postdose (Figs. 2E, F). The Tmax may be observed at any time point on the plateau, with the median at 24 hours for PBMCs and 72 hours for CD4+ cells. The median normalized Cmax in total PBMCs for TFV-DP was comparable after microdosing versus after the standard dose (13.1 versus 10.4 fmol/106 cells, P = 0.35). In CD4+ cells, the median normalized Cmax of intracellular TFV-DP was 1.6-fold higher versus after receiving the standard dose (13.17 versus 5.11 fmol/106 cells, P = 0.08, Tables 1 and 2). In Wilcoxon signed rank test, the normalized intracellular TFV-DP AUCinf was 1.43-fold and 1.28-fold greater with the microdose when compared to the standard dose for PBMCs and CD4+ cells, respectively (P > 0.05 for both, Table 2). Half-life estimation based on only 2 terminal time points was similar between the 2 dosing regimens.
Comparison of PK of Intracellular Phosphates in CD4+ Cells and PBMCs
Intracellular ZDV-TP concentrations were lower in CD4+ cells (P = 0.03) compared with PBMCs in subjects receiving the standard dose regimen, but this difference was smaller and not statistically significant following the microdose regimen (P = 0.08, Table 3). The median ratio of the PBMC to CD4+ cell AUCinf was 3.81 (range, 2.10–6.37) for the standard dose regimen and 2.00 (range 0.76–3.62) for the microdose regimen (Table 3). Half-life estimation of ZDV-TP was not different for CD4+ cells compared with PBMCs in both dosing regimens (Tables 1 and 3).
In both the microdose regimen and the standard dose regimen, TFV-DP showed a similar PK profile for PBMCs and CD4+ cells (P > 0.05 for Cmax, AUCinf, and t 1/2). The median ratio of PBMCs to CD4+ cell AUCinf was 1.04 (range, 0.48–2.72) for the microdose regimen and 2.15 (range, 0.79–3.55) for the standard dose regimen (Table 3).
In comparing PK parameters calculated after the microdose or standard dosing regimens in this specific target cell subset, CD4+ cells demonstrate the same trend as PBMCs. For ZDV-TP, estimated Cmax and AUCinf were higher after the microdose compared with the standard dose in both CD4+ cells and total PBMCs. For TFV-DP, no statistically significant difference in TFV-DP PK was observed between the microdose and standard dosing regimens in either CD4+ cells or PBMCs (Tables 1 and 2).
The Biphasic Elimination of Intracellular TFV-DP
Following the standard dosing regimen, intracellular TFV-DP concentrations peaked around 12 hours postdosing, then plateaued between 12 and 72 hours (Fig. 2A). After the plateau, there was a slow elimination phase with an estimated t 1/2 of 64 hours and 100 hours in PBMC and CD4+ cells, respectively, but based on only 2 terminal time points (72 and 168 hours postdosing). This biphasic profile was observed in 5 of 6 subjects. Figure 2A plots the plasma TFV and intracellular TFV-DP of PBMC after a single dose of 300 mg TDF. The TFV-DP concentration continued to increase even after the TFV concentration in plasma dropped to near background.
Figure 2B illustrates the ratio of absolute molar concentration of extracellular TFV and intracellular TFV-DP (with a volume of 0.4 μL per million cells used to estimate concentration16,17). The molar ratio of plasma to intracellular TFV-DP was around 100-fold at 4 hours postdose, declined to around 2-fold at 72 hours, and then fell below 1.0 at 168 hours. These results indicated that the positive concentration gradient of TFV between plasma and intracellular compartments persisted until 72 hours postdosing.
In this study, we examined the PK profile of 2 NRTIs after microdose and standard therapeutic dosing regimens. For ZDV, plasma PK showed linearity over a 3000-fold dosing range, but the normalized intracellular ZDV-TP was several folds higher with the microdose compared with the standard dosing regimen. For TFV, the normalized plasma AUCinf was 1.5-times higher with the microdose regimen, possibly indicating higher oral bioavailability, but intracellular TFV-DP PK was linear over the 3000-fold dose range tested. As has been suggested previously, the ability to precisely predict human PK from a microdosing study will vary from molecule to molecule.18–20
The different results for intracellular ZDV-TP and TFV-DP may reflect the different kinases involved in their phosphorylation pathways. ZDV is phosphorylated sequentially by thymidine kinase, thymidylate kinase, and nucleoside diphosphate kinase (NDP), with thymidylate kinase acting as a rate-limiting enzyme in this process.21 An earlier study showed that the phosphorylation of ZDV-MP to ZDV-DP is characterized by a high Km and low Kcat, and that intracellular ZDV-MP concentrations were much lower than the K m of this enzyme after a 300 mg dose.7 Because the concentration of ZDV-MP is likely to be far below the Km with either the standard 300 mg dose or the microdose (100 μg), the rate of conversion of ZDV to ZDV-TP should be similar in either case. However, ZDV-MP has been reported to have a substrate suppression effect on thymidylate kinase.21 With microdose of ZDV, this suppression might be reversed and the enzyme may become more efficient. This could have contributed to the higher ZDV phosphorylation observed with the microdose regimen.
Tenofovir is phosphorylated by adenylate kinase to TFV-MP and subsequently phosphorylated by NDP (NDPK) to TFV-DP. In vitro data suggest that this second step can also be accomplished by pyruvate kinase and creatine kinase.22 With TFV and TFV-MP as substrates, both phosphorylation steps are also characterized by low Kcat and high Km.22,23 In other words, phosphorylation is carried out at low velocity and high capacity, which may explain the slow accumulation of TFV-DP in cells and the linearity of PK across the 3000-fold range of doses that we evaluated in this study.
Studying phosphorylation in the biological target cell subset in vivo may provide valuable information applicable to future drug use and development. It has been reported that ZDV-TP formation is lower in CD4+ cells than in total PBMCs, whereas lamivudine triphosphate concentrations are the same among different cell types.9 Here, we compared the intracellular phosphorylated concentrations of ZDV and TFV in CD4+ cells versus total unfractionated PBMCs. ZDV-TP concentrations were lower in CD4+ cells in the standard dose regimen, whereas TFV-DP concentrations were not different in these subsets of cells.
The reason for the different phosphorylation of ZDV in specific cell types is not fully understood, and the result of this study supports the existence of a rate-limiting step or nonlinear phosphorylation specific to ZDV in CD4+ cells. The difference of ZDV-TP concentrations in CD4+ cells compared with PBMCs was statistically significant with standard dosing (Wilcoxon signed rank test, P < 0.05), but not with microdosing. The difference in ZDV-TP concentrations after microdose and standard dose regimens was larger in CD4+ cells compared with PBMCs (11.9-fold versus 3.9-fold), unlike TFV-DP (similar concentration ratios in PBMCs and CD4+ cells after the 2 dosing regimens). These observations further support the existence of a rate-limiting step in the formation of ZDV-TP in CD4+ cells.
AMS analysis of the intracellular concentrations of ZDV-TP and plasma TFV yielded excellent concordance with published data.11,24–26 The longer estimated half-life and higher AUCinf of ZDV in plasma in this study was almost certainly because AMS measures the sum of ZDV and its metabolites, mainly ZDV-glucuronide. For TFV-DP, single dose PK for TFV-DP in PBMC has not been reported in the literature, and all PBMC TFV-DP data were collected from subjects who have reached steady state. It is possible to estimate the steady state Css based on the PK profile after a single dose if the PK is linear and stationary. If we use Css = AUCinf/tau, the derived mean Css with 300-mg once-daily dose is about 60 fmol/106 cells. This derived steady state TFV-DP concentration agrees with that reported in the literature.24,27–29
We observed a significant plateau phase for intracellular TFV-DP concentrations between 12 and 72 hours after a single dose, followed by a more conventional but prolonged elimination phase. A prolonged plateau phase suggests balanced formation and elimination of TFV-DP. Estimation of the t 1/2 of TFV-DP is complicated by this multiphasic elimination, that is, plateau phase followed by prolonged elimination phase, and this may explain the wide range of elimination half-lives reported in vitro (50 hours in resting T cells)8,30 and in patients taking TDF (100–150 hours).28,31 In our study, intracellular TFV-DP formation seemed to continue as plasma TFV concentrations fell to undetectable levels. A detailed calculation of the absolute ratio of concentrations of intracellular and extracellular TFV found that the positive gradient from outside the cell to inside the cell persisted during the TFV-DP formation and plateau phases and for up to 72 hours postdose (Fig. 2B). This suggests that it is not necessary to posit a reservoir or accumulation of intracellular TFV-DP precursors such as TFV or TFV-MP. Recent data also proved little accumulation of TFV or TFV-MP in PBMCs in vivo.27 Our single-dose studies allowed demonstration of a hysteresis of TFV-DP formation relative to plasma TFV and a biphasic elimination profile of TFV-DP elimination. This aspect of TFV-DP PK has not been reported previously in the literature. These findings support the observations of Patterson's study, where TDF-DP concentrations were detectable in rectal and vaginal mucosal homogenates as long as 14 days after a single dose.25
TDF is widely used for the treatment of HIV infection and also shows promise in preexposure prophylaxis for HIV infection.32,33 Our findings may have potential implications for future prevention studies using TDF. The 12-hour time lag before the beginning of the TFV-DP plateau after a single dose suggests that the first dose of TDF for PrEP may need to be taken at least several hours before exposure to be effective depending on the effective TFV-DP concentration. On the other hand, the long plateau and slow elimination of TFV-DP indicates that a daily dosing regimen should be quite forgiving of missed doses if used continuously.
For the comparison of microdose and standard dosing regimens, we used a fixed sequence design with paired analysis to compensate for interindividual variability, our study was therefore informative despite the small number of subjects. Carryover of intracellular phosphates from the microdose phase was observed, but in only 2 subjects in each arm and the amount was too small to significantly influence the results of the standard dose phase. A fixed sequence design has the advantage over a crossover design of avoiding potential consequences of induction or inhibition of drug metabolizing enzymes, transporters, kidney function, and other potential drug toxicities that might change PK after a standard dose of ZDV or TDF. AMS may facilitate early development of investigational nucleoside analogs through microdosing, but rate-limited metabolism complicates interpretation of intracellular metabolism with microdosing studies. When rate-limiting steps potentially present, caution should be exercised in extrapolating from microdose to standard dose.
The authors would like to thank Tracy King and Lane Bushman for training in the separation of TFV-DP and ZDV-TP. The authors would also like to thank our research coordinators, Christine Radebaugh and Stephanie Everts, and the volunteers who participated in this study.
1. Boddy AV, Sludden J, Griffin MJ, et al.. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin Cancer Res. 2007;13:4164–4169.
2. Gao L, Li J, Kasserra C, et al.. Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose
absolute bioavailability studies. Anal Chem. 2011;83:5607–5616.
3. Yamane N, Tozuka Z, Kusama M, et al.. Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose
clinical studies. Pharm Res. 2011;28:1963–1972.
4. Lappin G, Kuhnz W, Jochemsen R, et al.. Use of microdosing to predict pharmacokinetics
at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther. 2006;80:203–215.
5. Kurihara C. Ethical, legal, and social implications (ELSI) of microdose
clinical trials. Adv Drug Deliv Rev. 2011;63:503–510.
6. Chen J, Garner RC, Lee LS, et al.. Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther. 2010;88:796–800.
7. Lavie A, Schlichting I, Vetter IR, et al.. The bottleneck in AZT activation. Nat Med. 1997;3:922–924.
8. Robbins BL, Srinivas RV, Kim C, et al.. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998;42:612–617.
9. Anderson PL, Zheng JH, King T, et al.. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS. 2007;21:1849–1854.
10. Louissaint NA, Nimmagadda S, Fuchs EJ, et al.. Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men. J Acquir Immune Defic Syndr. 2011;59:10–17.
11. King T, Bushman L, Anderson PL, et al.. Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;831:248–257.
12. King T, Bushman L, Kiser J, et al.. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate
in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;843:147–156.
13. Liberman RG, Tannenbaum SR, Hughey BJ, et al.. An interface for direct analysis of (14)c in nonvolatile samples by accelerator mass spectrometry. Anal Chem. 2004;76:328–334.
14. Naesens L, Bischofberger N, Augustijns P, et al.. Antiretroviral efficacy and pharmacokinetics
of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother. 1998;42:1568–1573.
15. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics
. Clin Pharmacokinet. 2004;43:595–612.
16. van Kampen JJ, Reedijk ML, Burgers PC, et al.. Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. PLoS One. 2010;5:e11409.
17. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother. 2004;54:982–990.
18. Ieiri I, Nishimura C, Maeda K, et al.. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose
and therapeutic dose. Pharmacogenet Genomics. 2011;21:495–505.
19. Maeda K, Takano J, Ikeda Y, et al.. Nonlinear pharmacokinetics
of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther. 2011;90:263–270.
21. Jorajuria S, Dereuddre-Bosquet N, Becher F, et al.. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004;9:519–528.
22. Koch K, Chen Y, Feng JY, et al.. Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives. Nucleosides Nucleotides Nucleic Acids. 2009;28:776–792.
23. Topalis D, Alvarez K, Barral K, et al.. Acyclic phosphonate nucleotides and human adenylate kinases: impact of a borano group on alpha-P position. Nucleosides Nucleotides Nucleic Acids. 2008;27:319–331.
24. Baheti G, Kiser JJ, Havens PL, et al.. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother. 2011;55:5294–5299.
25. Patterson KB, Prince HA, Kraft E, et al.. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112–114.
26. Gagnieu MC, Barkil ME, Livrozet JM, et al.. Population pharmacokinetics
of tenofovir in AIDS patients. J Clin Pharmacol. 2008;48:1282–1288.
27. Bushman LR, Kiser JJ, Rower JE, et al.. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011;56:390–401.
28. Hawkins T, Veikley W, St Claire RL 3rd, et al.. Intracellular pharmacokinetics
of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39:406–411.
29. Kiser JJ, Aquilante CL, Anderson PL, et al.. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:298–303.
30. Borroto-Esoda K, Vela JE, Myrick F, et al.. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther. 2006;11:377–384.
31. Delaney WE 4th, Ray AS, Yang H, et al.. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471–2477.
32. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174.
33. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011;25:63–71.